Takeda's ARB Enters Phase III Trials In Japan As Company Moves To Acquire U.S. Biopharmaceutical Firm IDM
This article was originally published in PharmAsia News
Executive Summary
TOKYO - Takeda Pharmaceutical's angiotensin receptor blocker compound TAK-536 has entered Phase III clinical trials in Japan, just as the country's largest drug maker moves to complete its tender offer for the acquisition of U.S. biotech outfit IDM Pharma